Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

被引:0
|
作者
Bunick, Christopher G. [1 ,2 ]
Bhatia, Neal [3 ]
Del Rosso, James [4 ]
Draelos, Zoe D. [5 ]
Eichenfield, Lawrence F. [6 ]
Kircik, Leon H. [7 ,8 ,9 ,10 ]
Lebwohl, Mark G. [7 ]
Gooderham, Melinda [11 ,12 ]
Green, Lawrence J.
Hebert, Adelaide A. [14 ]
Vender, Ronald B. [15 ]
Zirwas, Matthew [16 ,17 ]
Simpson, Eric L. [13 ,18 ]
Gold, Linda Stein [19 ]
Seal, Melissa [20 ]
Snyder, Scott [20 ]
Osborne, David W. [20 ]
Burnett, Patrick [20 ]
Higham, Robert C. [20 ]
Chu, David H. [20 ]
Berk, David R. [20 ]
机构
[1] Yale Univ, Dept Dermatol, New Haven, CT USA
[2] Yale Univ, Program Translat Biomed, New Haven, CT USA
[3] Therapeut Clin Res, San Diego, CA USA
[4] JDR Dermatol Res, Las Vegas, NV USA
[5] Dermatol Consulting Serv, High Point, NC USA
[6] Univ Calif San Diego, Radys Childrens Hosp San Diego, Dept Dermatol & Pediat, San Diego, CA USA
[7] Icahn Sch Med Mt Sinai, New York, NY USA
[8] Indiana Med Ctr, Indianapolis, IN USA
[9] Phys Skin Care PLLC, Louisville, KY USA
[10] Skin Sci PLLC, Louisville, KY USA
[11] SkiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada
[12] Queens Univ, Peterborough, ON, Canada
[13] George Washington Univ, Sch Med, Rockville, MD USA
[14] UT Hlth McGovern Med Sch, Houston, TX USA
[15] Dermatrials Res Inc, Hamilton, ON, Canada
[16] Dermatologists Cent States, Prob Med Res, Bexley, OH USA
[17] Ohio Univ, Bexley, OH USA
[18] Oregon Hlth & Sci Univ, Portland, OR USA
[19] Henry Ford Med Ctr, Detroit, MI USA
[20] Arcutis Biotherapeut Inc, Westlake Village, CA USA
关键词
topical roflumilast; atopic dermatitis; psoriasis; seborrheic dermatitis; local tolerability;
D O I
10.1093/bjd/ljad498.012
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
504
引用
收藏
页码:II9 / II10
页数:2
相关论文
共 25 条
  • [1] Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
    Bunick, Christopher G.
    Bhatia, Neal
    Del Rosso, James
    Draelos, Zoe D.
    Eichenfield, Lawrence F.
    Kircik, Leon H.
    Lebwohl, Mark G.
    Gooderham, Melinda
    Green, Lawrence J.
    Hebert, Adelaide A.
    Vender, Ronald B.
    Zirwas, Matthew
    Simpson, Eric L.
    Gold, Linda Stein
    Seal, Melissa
    Snyder, Scott
    Osborne, David W.
    Burnett, Patrick
    Higham, Robert C.
    Chu, David H.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [2] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [3] Nonclinical Safety and Toxicokinetics of MnTE-2-PyP (BMX-010), a Topical Agent in Phase 2 Trials for Psoriasis and Atopic Dermatitis
    Gad, Shayne C.
    Sullivan, Dexter W., Jr.
    Mujer, Cesar V.
    Spainhour, Charles B.
    Crapo, James D.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2019, 38 (04) : 291 - 302
  • [4] Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bhatia, Neal
    DuBois, Janet
    Forman, Seth B.
    Gooderham, Melinda
    Green, Lawrence
    Guenthner, Scott T.
    Hebert, Adelaide A.
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Kato, Saori
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 986 - 993
  • [5] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [6] Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children
    Simpson, Eric L.
    Hebert, Adelaide A.
    Browning, John
    Serrao, Rocco T.
    Sofen, Howard
    Brown, Philip M.
    Piscitelli, Stephen C.
    Rubenstein, David S.
    Tallman, Anna M.
    DERMATOLOGY AND THERAPY, 2025, 15 (01) : 111 - 124
  • [7] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [8] Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
    Reich, K.
    DeLozier, A. M.
    Nunes, F. P.
    Thyssen, J. P.
    Eichenfield, L. F.
    Wollenberg, A.
    Terres, J. A. Ross
    Watts, S. D.
    Chen, Y-F
    Simpson, E. L.
    Silverberg, J., I
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1521 - 1530
  • [9] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Blauvelt, Andrew
    Gooderham, Melinda
    Bhatia, Neal
    Langley, Richard G.
    Schneider, Shannon
    Zoidis, John
    Kurbasic, Azra
    Armstrong, April
    Silverberg, Jonathan, I
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
  • [10] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
    Andrew Blauvelt
    Melinda Gooderham
    Neal Bhatia
    Richard G. Langley
    Shannon Schneider
    John Zoidis
    Azra Kurbasic
    April Armstrong
    Jonathan I. Silverberg
    Dermatology and Therapy, 2022, 12 : 2499 - 2516